Fig. 4

Protective effects of SZYQD in the OVA + LPS asthmatic model. (A) the procedure of OVA + LPS asthmatic model. (B) HE staining of lung tissue in different groups. Normal (N), asthma model (A), SZYQD low-dose treated (A + SL) group and SZYQD high-dose treated (A + SH) groups. Magnification: 200X. (C) HE scores in different groups. (D-E) mRNA expression of MUC5AC and IL6 in mouse lung was detected with RT-qPCR. (F) The expression levels of p-AKT and p-p65 protein levels were measured by western blot. (G-H) Quantification of p-p65 and p-AKT. Data mean ± S, ** P < 0.01,* P < 0.05, n = 6–7